PAM50 is a list of 50 genes that classify breast cancer into one of four intrinsic subtypes: Luminal A, Luminal B, HER2-enriched, Basal-like and Normal-Like1.
These subtypaes have been shown to be prognostic in both un-treated (i.e. no adjuvant systemic therapy) and tamoxifen treated patient populations.
Using NanoString’s RUO PAM50 panel, quantification of the PAM50 genes can now be performed in surgically resected breast cancer samples more rapidly and reproducibly than is possible using qPCR or RNASeq.
Propath offers a complete, managed service for analysis of breast cancer samples using NanoString’s PAM50 panel.
Analysis is for Research Use Only.
Simply send us your samples and receive publication ready data in as little as three weeks.
Our experience across a range of platforms for spatial biology allows us to recommend the most appropriate platform for each research project.
We understand the strengths and limitations of each platform – and how to get the best out of them.